>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Tacrolimus 他克莫司; FK506; Fujimycin; FR900506

Tacrolimus (FK506)，大环内酯类，与 FK506 结合蛋白 (FKBP) 结合形成复合物并抑制钙调神经磷酸酶 (calcineurin phosphatase)，从而抑制 T 淋巴细胞信号转导和 IL-2 转录。具有强免疫抑制特性。

货号：
TK0361
规格：

10mg

50mg

100mg
价格：
￥0.00

产品参数

CAS No.	104987-11-3
生物活性	Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.
分子式	C44H69NO12
分子量	804.02
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	4°C, protect from light
溶解性数据	DMSO : ≥ 150 mg/mL (186.56 mM)
体内研究	The therapeutic effect of Tacrolimus is investigated on progression and perpetuation of colitis by administering Tacrolimus to Dextran sulfate sodium (DSS)-treated mice from Days 10 to 16 or to 23. At Days 17 and 24, colon length is significantly shortened, and colon weight is significantly higher in DSS-treated control animals than in normal animals. In addition, colon weight per unit length in the control group is more than twice that in the normal group. While both 7 and 14 d treatment with Tacrolimus significantly suppresses increases in colon weight per unit length in DSS-treated animals compared with the control group, this treatment does not actually restore the colon shortening. In addition, this inhibitory effect of Tacrolimus on increases in colon weight per unit length is more pronounced with 14-d than 7-d treatment, as shown by the inhibitory percentages (59% vs. 28%).
体外研究	Tacrolimus (FK506) inhibits calcium-dependent events, such as IL-2 gene transcription, NO synthase activation, cell degranulation, and apoptosis. Tacrolimus also potentiates the actions of glucocorticoids and progesterone by binding to FKBPs contained within the hormone receptor complex, preventing degradation. The agent may enhance expression of the TGFβ-1 gene in a fashion analogous to that demonstrated for CsA. T cell proliferation in response to ligation of the T cell receptor is inhibited by Tacrolimus. Treatment with a low concentration of Tacrolimus (FK506,10 μg/L) does not significantly affect the proliferation of MH3924A cells (P=0.135). Upon treatment with higher concentrations of Tacrolimus (100-1,000 μg/L), the proliferation of MH3924A cells is significantly enhanced (P<0.01). Treatment with AMD3100 at any concentration (10, 50 or 100 μg/L), has no obvious effect on MH3924A cell proliferation (P>0.05). However, when different concentrations of AMD3100 are combined with 100 μg/L Tacrolimus, the in vitro proliferation of MH3924A cells is increased (P<0.01).
文献	•J Extracell Vesicles. 2019 Dec 27;9(1):1709262. •Biomaterials. 2021, 120757. •Theranostics. 2021 Mar 5;11(10):5045-5060. •Theranostics. 2020 May 16;10(14):6483-6499. •Theranostics. 2018 Jan 1;8(4):878-893. •Nano Lett. 2019 Jan 9;19(1):124-134. •Proc Natl Acad Sci U S A. 2021 Jan 12;118(2):e2009539118. •J Control Release. 2020 Dec 10;328:237-250. •Cell Rep. 2021 Jul 20;36(3):109404. •Cell Rep. 2021, 108959. •Nano Res. 11, 6086-6101(2018). •Cell Syst. 2018 Apr 25;6(4):424-443.e7. •Pharmacol Res. 2021, 105382. •Cell Biol Toxicol. 2021 Aug 8. •Drug Deliv. 2021 Dec;28(1):1759-1768. •Biomater Sci. 2020 Oct 7;8(19):5282-5292. •Cell Commun Signal. 2021 Oct 11;19(1):103. •J Cell Sci. 2019 May 20;132(10):jcs227777. •Int J Pharm. 2019 Dec 13;575:118951. •Mediat Inflamm. 2019 Dec 17;2019:4176974. •Toxins (Basel). 2019 Jun 18;11(6):349. •Skelet Muscle. 2020 Apr 22;10(1):10. •Brain Res. 2019 May 15;1711:68-76. •Acta Trop. 2020 Dec;212:105708. •Transpl Immunol. 2021 Jun 30;101434. •Research Square Preprint. 2020 Dec. •Dis Model Mech. 2019 Jan 28;12(1). pii: dmm036830. •Patent. US20180263995A1. •Exp Hematol Oncol. 2016 Jul 29;5:22. •Am J Digest Dis. 2015;2(2):95-99. •Int J Physiol Pathophysiol Pharmacol. 2015 Mar 20;7(1):54-60.
纯度及产品资料	98%

推荐产品